## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-3.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($89.52)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Invesco Ltd. Acquires 232,268 Shares of Incyte Corporation $INCY**
- Source: MarketBeat | 20251208T120836 | Somewhat-Bullish | Relevance: 99%
-  Invesco Ltd. increased its stake in Incyte Corporation (NASDAQ:INCY) by 7.3% during the second quarter, acquiring an additional 232,268 shares and bringing its total holdings to 3,401,018 shares valued at $231.6 million. The biopharmaceutical company has shown strong earnings, with a reported $2.26 EPS for the quarter, surpassing analyst estimates, and its stock has performed well, opening at $102.52 with a market cap of $20.13 billion.

**2. Incyte presents data showing 90% response rate for blood cancer drug**
- Source: StreetInsider | 20251208T213431 | Bullish | Relevance: 99%
-  Incyte Corporation (NASDAQ: INCY) announced positive clinical trial data for its experimental drug INCA033989, showing a 90% hematologic response rate in essential thrombocythemia patients at higher doses. The drug, a monoclonal antibody targeting mutant calreticulin, also achieved an 83.3% complete hematologic response in the higher dose group. Incyte plans to initiate a registrational program for INCA033989 in the first half of next year.

**3. Incyte stock holds Market Perform rating at Citizens on CALR therapy lead**
- Source: Investing.com | 20251209T112451 | Bullish | Relevance: 99%
-  Citizens maintained its Market Perform rating on Incyte (NASDAQ:INCY) due to its first-mover advantage in CALR-mutant myeloproliferative neoplasms (MPNs) therapy with its '989 therapy. The company has seen significant momentum, with shares up 40% year-to-date, and positive revisions to earnings expectations from 13 analysts. Despite increasing competition, Incyte is considered the leader, though continued differentiation will be crucial.

**4. Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia**
- Source: marketscreener.com | 20251208T155207 | Bullish | Relevance: 99%
-  Incyte announced that its experimental treatment, INCA033989, for essential thrombocythemia has received FDA Breakthrough Therapy designation. This designation aims to accelerate development, supported by Phase 1 data showing good tolerability and normalization of platelet counts, with enhanced responses at higher doses. Incyte plans to launch a registry program for patients resistant or intolerant to existing therapies in the first half of 2026.

**5. Incyte Corporation $INCY Shares Purchased by American Century Companies Inc.**
- Source: MarketBeat | 20251208T120836 | Bullish | Relevance: 99%
- American Century Companies Inc. increased its stake in Incyte Corporation ($INCY) by 20.6% in the second quarter, bringing their total holdings to 78,161 shares valued at $5.32 million. Other institutional investors also modified their positions. Analysts have a consensus "Hold" rating for Incyte, with an average price target of $93.85. The article also provides details on Incyte's financial performance, recent insider transactions, and company profile.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 12.5x attractive for 13% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.0B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 12.5 |
| Current P/E | 14.1 |
| YoY Growth | 12.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -4.6% to -8.6% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 12.6pp (needs >4.0% for momentum thesis). AM_20 at -6.7% indicates price below own 20MA trend. Underperforming sector by 5.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-1.24), momentum weakening. RSI neutral at 41. Elevated volume (1.3x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -8.55% (CS: 3) | Weak |
| RSI_14 | 40.8 | Neutral |
| MACD Histogram | -1.24 | Bearish |
| vs SMA20 | 0.934x | Below |
| vs SMA50 | 1.010x | Above |
| vs SMA200 | 1.261x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.70
- **Stop Loss:** $89.52 (7.4% risk)
- **Target:** $111.06 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 69
- **Position Value:** $6,672.30
- **Portfolio %:** 6.67%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $1.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*